Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Wednesday, September 19, 2018 · 462,433,416 Articles · 3+ Million Readers

Celsion Corporation to Hold Second Quarter 2018 Financial Results Conference Call on Tuesday, August 14, 2018

LAWRENCEVILLE, N.J, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2018 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Tuesday, August 14, 2018. To participate in the call, interested parties may dial 1-877-260-1479 (Toll-Free/North America) or 1-334-323-0522 (International/Toll) and ask for the Celsion Corporation 2nd Quarter 2018 Earnings Call (Conference Code: 1373876) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.

The call will be archived for replay on Tuesday, August 14, 2018 and will remain available until Tuesday, August 28, 2018. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 1373876.  An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Tuesday, August 14, 2018.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.  The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).

/EIN News/ --

Celsion Investor Contact
                    Jeffrey W. Church
                    Sr. Vice President and CFO
                    609-482-2455
                    jchurch@celsion.com

Primary Logo

Powered by EIN News
Distribution channels:
Submit your press release